Overview

VI-1121 for the Treatment Alzheimer's Disease

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.

Phase:

Phase 2

Details

Lead Sponsor:

VIVUS, Inc.

Collaborator:

Medpace, Inc.